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Axonal myelination is essential for rapid saltatory
impulse conduction in the nervous system, and mal-
formation or destruction of myelin sheaths leads to
motor and sensory disabilities. DNA methylation is
an essential epigenetic modification during mamma-
lian development, yet its role in myelination remains
obscure. Here, using high-resolution methylome
maps, we show that DNA methylation could play a
key gene regulatory role in peripheral nerve myelina-
tion and that S-adenosylmethionine (SAMe), the prin-
cipal methyl donor in cytosine methylation, regulates
the methylome dynamics during this process. Our
studies also point to a possible role of SAMe in
establishing the aberrant DNA methylation patterns
in amousemodel of diabetic neuropathy, implicating
SAMe in the pathogenesis of this disease. These
critical observations establish a link between SAMe
and DNA methylation status in a defined biological
system, providing a mechanism that could direct
methylation changes during cellular differentiation
and in diverse pathological situations.
INTRODUCTION
Axonal myelination is essential for rapid saltatory impulse con-
duction, and malformation or destruction of myelin sheaths1024 Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc.can lead to severe motor and sensory disabilities (Suter and
Scherer, 2003). In the peripheral nervous system, genome-
wide changes in gene expression characterize both the differen-
tiation of myelinating Schwann cells (Nagarajan et al., 2002;
Verheijen et al., 2003) and development of neuropathies,
including diabetic neuropathy (Pande et al., 2011). The coordi-
nated changes in gene expression patterns associated with
Schwann cell myelination are controlled transcriptionally by an
elaborate network of transcription factors (TFs), including Egr2,
Sox10, Oct6, YY1, and NFkB (Jessen and Mirsky, 2005; Pereira
et al., 2012), recruitment of chromatin-remodeling complexes to
regulatory regions of keymyelin genes (Hung et al., 2012;Weider
et al., 2012), and possibly by histone deacetylation (Pereira et al.,
2012). In addition, microRNAs and RNA-binding proteins play a
crucial role in the posttranscriptional regulation of these global
changes in gene expression (Iruarrizaga-Lejarreta et al., 2012;
Pereira et al., 2012).
DNAmethylation is a key epigenetic mechanismwith essential
functions, including repression of target promoters, genomic
imprinting, silencing of transposable elements, andmaintenance
of genomic integrity (Jaenisch and Bird, 2003). Methylation
occurs on the fifth position of cytosine, mostly in the context of
CpG dinucleotides, and is catalyzed by a family of three
conserved DNA methyltransferase enzymes, Dnmt1, Dnmt3a,
and Dnmt3b (Smith and Meissner, 2013). During the methylation
process, DNMTs transfer the methyl group from the principal
methyl donor SAMe to cytosine residues, generating S-adeno-
sylhomocysteine (SAH) (Lu and Mato, 2012). Mouse functional
studies and, more recently, large-scale DNA methylation map-
ping have provided important insights into the regulatory role
of DNA methylation in mammalian development (Smith and
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SAMe Regulates the Schwann Cell DNA MethylomeMeissner, 2013). In particular, DNA methylome characterization,
often at single-base resolution, has enabled the genome-wide
identification of changes in DNA methylation patterns during
somatic lineage commitment with associated changes in gene
expression at promoter regions and regulatory elements,
including enhancers (Jones, 2012).
In this study, we used high-resolution genomic maps to
examine the methylome dynamics during Schwann cell myelina-
tion in vivo. Like other somatic cellular differentiation paradigms
(Calvanese et al., 2012; Lee et al., 2012; Shearstone et al., 2011),
we found that Schwann cell myelination was characterized by
global DNA demethylation, which was associated with activation
of critical myelination-associated genes, particularly those
involved in synthesis of lipid, a critical component of myelin.
Importantly, our observations support the notion that levels of
SAMe play a critical role in regulating the methylation status of
myelinating Schwann cells. Peripheral nerves from mice with
enforced elevated levels of SAMe were characterized by DNA
hypermethylation globally and at promoter and enhancer regions
of several lipid synthesis genes. This correlated with an altered
lipid profile, probably contributing to the peripheral myelin
defects in these mice. Furthermore, we showed that reduced
SAMe levels correlated with DNA demethylation in peripheral
nerves of a mouse model of diabetic neuropathy, suggesting a
possible role of SAMe in the pathogenesis of this disease.
Taken together, this study shows that Schwann cell myelina-
tion is characterized by widespread DNA methylation changes
that probably play a key gene regulatory role. These methylation
dynamics are dependent on a tight control of SAMe levels, and
imbalances to its levels probably lead to aberrant DNA methyl-
ation patterns and consequently gene expression changes
during development of neuropathies.
RESULTS
Genome-Scale DNA Methylation Maps of Schwann Cell
Myelination
To examine DNA methylation dynamics during Schwann cell
myelination, we isolated sciatic nerves from mice at different
ages that broadly correspond to the main stages of the myelina-
tion process (Jessen and Mirsky, 2005). Thus, nerves were
obtained from newborn mice (NB), which are highly enriched
for immature Schwann cells, postnatal day 10 (P10) nerves,
which contain mostly actively myelinating Schwann cells, and
P60 nerves, which contain terminally differentiated myelinating
Schwann cells.
DNA methylation mapping was performed by reduced repre-
sentation bisulfite sequencing (RRBS), which enables quantita-
tive methylation analysis at single-base resolution of relatively
small cell numbers (Smith et al., 2012). Methylation levels of
individual CpGs were combined over nonoverlapping 1 kb tiling
regions to increase statistical power for subsequent analyses
(Bock, 2012). For each stage, two to three biological replicates
were obtained from different mice with high reproducibility and
expected genomic coverage (Figures S1A and S1B available
online). RRBS, in our case, was particularly suitable since it
allowed us to study DNA methylation at gene regulatory ele-
ments such as promoter regions, given its strong bias at detect-ing methylation changes in genomic regions of medium to high
CpG density (Bock et al., 2010).
To examine the impact of DNA methylation in the overall
process of myelination, we compared the DNA methylation
patterns in the progenitor cells (immature Schwann cells) and
the terminally differentiated cells (mature myelinating Schwann
cells) (Figure 1A). From the pairwise analysis, methylation levels
of 73,317 1 kb tiles were obtained (Table S1).We found that there
was a reduction in the proportion of regions with high methyl-
ation levels (R80%) in P60 nerves compared to NB nerves
(Figure 1B). Next, we compared changes in regional DNA
methylation by classifying methylation levels of each 1 kb tile in
P60 nerves relative to NB nerves as differentially methylated
regions (DMRs) if the percentage methylation difference ex-
ceeded 20% and had a q value < 0.05. We found that there
was about a 9-fold higher number of hypomethylated than
hypermethylated 1 kb tiling regions (Figure 1C). The DMRs
were distributed across all chromosomes (Figure 1E) and were
present at promoter regions, although the large majority was
found in gene bodies and intergenic regions (Figure 1F). Interest-
ingly, putative enhancers (identified by presence of H3K4me1)
(Shen et al., 2012) and repeat regions were significantly enriched
(Figure 1G). Comparison of the methylation levels of the DMRs
showed a substantial reduction in median methylation levels in
P60 nerves in 1 kb tiling regions (Figure 1D) and in other genomic
regions (Figures S1C and S1D).
These results show that the myelination program proceeds
with marked DNA demethylation, and a substantial enrichment
of DMRs at gene regulatory regions (promoters and putative
enhancers) and repeat elements.
DNA Demethylation Correlates with Increased
Expression of Myelination-Specific Genes
In contrast to the global DNA demethylation seen during the
myelination process, gene expression changes showed about
an equal number of upregulated and downregulated genes
(Figure S2A). This is consistent with DNA methylation being
only one of other concerted factors in regulating gene expression
(Portela and Esteller, 2010). DNA demethylation was associated
with both upregulated and downregulated genes (Figure S2B),
suggesting that DNA demethylation is not always associated
with gene expression. This is similar to other somatic differenti-
ation paradigms (Bock et al., 2012; Calvanese et al., 2012; Lee
et al., 2012; Shearstone et al., 2011).
DNA demethylation, instead, has been shown to play an
important role during somatic cell differentiation by regulating
expression of a modest number of genes with cell-type-specific
functional roles (Bock et al., 2012; Calvanese et al., 2012; Lee
et al., 2012). Consistent with these findings, we found that critical
myelination-associated genes that were upregulated during
development had a concomitant loss of methylation in gene-
associated 1 kb tiles (Figure 2A) that were often annotated to
gene regulatory regions (promoters and putative enhancers)
(Figures S2C and S2D). These included genes encoding struc-
tural components of myelin (Mbp, Pmp22, Prx, and Cnp) and
transcriptional regulators (Lgi4, Nab1, and Nfatc1) (Figure 2B).
We found, in general, that there were a 4-fold higher number of
hypomethylated DMRs at different genomic regions associatedNeuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1025
Figure 1. Methylation Dynamics during Schwann Cell Myelination
(A) Stages of Schwann cell development used for RRBS analysis to showDNAmethylation dynamics during Schwann cell myelination. Progenitor cells (immature
Schwann cells) are enriched in NB peripheral nerves, and terminally differentiated cells (mature myelinating cells) are enriched in P60 peripheral nerves.
(B) Proportion of 1 kb tiles with high (R80%, green), intermediate (>20% and < 80%, red), and low (%20%, blue) percentage methylation levels.
(C) Violin plot shows about a 9-fold greater number of hypomethylated DMRs (blue dots) than hypermethylated DMRs (red dots) in P60 nerves. Black dots
represent regions with percentage methylation difference <20% and/or q value > 0.05.
(D) Boxplot showingmethylation levels of DMRs in 1 kb tiles. Boxplots correspond to center quartiles with black bar indicatingmedian, andwhiskers extend to the
most extreme data point, which is no more than 1.5 times the interquartile range from the box.
(E) Chromosome ideogram representing DMRs in P60 nerves compared to NB nerves (magenta, hypermethylated DMRs; green, hypomethylated DMRs).
(F) Histogram showing proportion of DMRs at relative distances from transcription start site (TSS), determined with GREAT software.
(G) Histogram showing enrichment of DMRs in different genomic regions, determined with EpiExplorer software.
See also Figure S1 and Table S1.
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SAMe Regulates the Schwann Cell DNA Methylomewith upregulated genes, including lipid metabolism genes
(example of myelination-associated genes, see below). This
led to an overall reduced methylation level (Figures S2E–S2G),
confirming that upregulation of genes during development is
more significantly associated with hypomethylation rather than
hypermethylation.
Gene ontology (GO) analysis has been an important tool to
demonstrate quantitatively that genome-wide DNA methylation
changes are significantly enriched for categories associated
with specific cellular differentiation paradigms (Bock et al.,
2012; Calvanese et al., 2012). Here, similarly, we found that
upregulated genes with a concomitant decrease in methylation
levels either in 1 kb tiling regions or gene regulatory regions
were enriched for functional categories associated with the
transcriptomic signature of Schwann cell myelination (Figure 2C;
Table S2). Among these enriched categories, lipid metabolism
was particularly interesting since myelin consists of tightly
compacted membranes, highly enriched in cholesterol and
lipids, and PNS myelin is severely affected in several lipid
metabolism disorders (Chrast et al., 2011). Here, we found that
genes encoding many of the enzymes involved in lipid meta-
bolism became demethylated during myelination (Figure 2D).1026 Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc.These included key regulators (Scap and Srebf1) and individual
members (e.g., Hmgcr, Mvk, and Pmvk) of cholesterol biosyn-
thetic pathways, as well as genes involved in triglyceride meta-
bolism (Dgat1, Lipe, and Scd1) and fatty acid metabolism
(Abca2 and Elovl7).
Taken together, demethylation at gene regulatory regions can
be associated with activation of genes, which form part of the
complex machinery of myelin formation, most notably the lipid
biosynthetic process.
Demethylation Is Regulated by Different Mechanisms
Next, we examined the mechanisms that could regulate these
methylation patterns. Establishment and maintenance of DNA
methylation at promoter and enhancer regions are strongly influ-
enced by transcription factor (TF) binding (Smith and Meissner,
2013). Here, we performed a TF motif enrichment analysis of
all hypomethylated 1 kb tiles and found a significant enrichment
of specific TF-binding sites, including YY1, NFkB, and Egr2,
which are critical regulators of Schwann cell myelination (Pereira
et al., 2012) (Figure 2E; Table S2). These results suggest that
DNA demethylation at regulatory regions of myelination-associ-
ated genes could be mediated by binding of these TFs.
Figure 2. Global Demethylation during Schwann Cell Myelination
(A) Scatterplot of percentage DNA methylation levels of 1 kb tiles, showing hypomethylated regions (blue) and hypermethylated regions (red) in P60 nerves,
relative to NB nerves. Selected genes with important functions in Schwann cell myelination are highlighted.
(B) Heatmap showing changes in expression of myelination-related genes from microarray data (Table S2) in P10 and P60 nerves, compared to NB nerves
(red-blue color scale), and methylation difference in P60 nerves relative to NB nerves (white boxes).
(C) GO analysis showing top Molecular and Cellular Function categories enriched in all upregulated genes, upregulated genes that become hypomethylated in
tiling regions, and upregulated genes that become hypomethylated at promoter and putative enhancer regions.
(D) Scheme of the cholesterol biosynthesis pathway inwhich the site of action of enzymes (blue) is shown (left). Heatmaps (right) showing changes in expression of
genes from microarray experiments associated with cholesterol biosynthesis and distinct aspects of lipid metabolism in P10 and P60 nerves compared to NB
nerves (red-blue color scale). Percentage methylation difference in P60 nerves relative to NB nerves is shown in white boxes.
(E) Table showing enrichment of transcription factor recognition motifs in hypomethylated 1 kb tiling regions using Genomatix RegionMiner. Each row represents
a cis-regulatory module with significant overrepresentation relative to a random set of mammalian promoters (Z score).
See also Figure S2 and Table S2.
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SAMe Regulates the Schwann Cell DNA MethylomeGeneration of the mature myelinating Schwann cells can be
conveniently divided into two overlapping phases. First, imma-
ture Schwann cells differentiate into promyelinating Schwann
cells, which then undergo extensive membrane wrapping and
compaction into myelin to generate mature myelinating
Schwann cells. RRBS analysis (Figures S1A and S1B; TableS3) showed that both phases were characterized by global
DNA demethylation with a higher number of hypomethylated
than hypermethylated regions, which resulted in a notable
reduction in median methylation levels of DMRs, although the
effect was more pronounced for the first developmental transi-
tion than for the second one (Figures 3A and 3B). Since DNANeuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1027
Figure 3. Methylation Dynamics and Methyltransferase Expression during Different Stages of Schwann Cell Myelination
(A and B) DNAmethylation changes (refer to Figures 1C and 1D) between actively myelinating Schwann cells (P10) relative to immature Schwann cells (NB) (A) and
mature myelinating Schwann cells (P60) relative to actively myelinating Schwann cells (P10) (B).
(C and D) DNA methyltransferases are downregulated during Schwann cell myelination, as shown by qPCR analysis (C) and western blotting (WB) (D).
(E) qPCR analysis of regulators associated with active DNA demethylation.
(F) Assay of total DNA methyltransferase and demethylase activity during Schwann cell myelination. Data are represented as mean ± SEM, *p < 0.01, n = 3,
Student’s t test.
See also Figure S3 and Table S3.
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SAMe Regulates the Schwann Cell DNA Methylomereplication has been associated with DNA demethylation during
somatic cellular differentiation (Shearstone et al., 2011) and the
first phase is characterized by a high proliferation rate (Woodhoo
and Sommer, 2008), we examined a possible contribution of
cellular division to this demethylation pattern. We found that a
16 hr treatment of Schwann cells with the mitogen NRG1 led
to a significant decrease in global DNAmethylation levels, which,
notably, was reduced by a block of cell-cycle progression (Fig-
ures S3A and S3B). Similarly, comparison of DNA methylation
levels in cAMP-treated cultures at 24 hr and 48 hr, an in vitro
model of progressive myelin differentiation, showed a decrease1028 Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc.in global DNA methylation levels in the more mature myelinated
state (48 hr cAMP treatment) (Figure S3C). These results show
that both cell division and myelin differentiation probably regu-
late the global DNA demethylation in the formation of mature
myelinated Schwann cells.
Next, we examined the expression of DNA methylation regu-
lators during Schwann cell myelination. Both by quantitative
PCR (qPCR) and western blotting, we found that levels of all
DNMTs were downregulated during development, an effect
more pronounced between P10 and NB nerves than between
P60 and P10 nerves (Figures 3C and 3D). Of the regulators
Neuron
SAMe Regulates the Schwann Cell DNA Methylomeimplicated in active demethylation (Bhutani et al., 2011),
Gadd45a,Gadd45b, andApobec1were upregulated (Figure 3E).
Measurement of total DNMT and DNA demethylase activity
broadly correlated with these observations (Figure 3F). Interest-
ingly, we found that there was a significant difference in the
activity of these enzymes between the P10 and NB stages, but
not between the P60 and P10 stages. The downregulation of
DNMT expression between NB and P10 nerves is probably
mediated by the transition from the highly proliferative immature
Schwann cells in NB nerves to the quiescent cells in P10 nerves,
since we found that high DNMT expression in cultured Schwann
cells maintained under proliferative conditions is reduced after
cell cycle block (Figure S3D). Similarly, downregulation of
DNMT expression between P10 and P60 nerves is probably
mediated by the myelin differentiation process since we found
significant downregulation of DNMT expression in vitro in
the more mature myelinated state (48 hr cAMP treatment)
(Figure S3E).
These results show that both formation and maturation of
myelinated Schwann cells are characterized by DNA de-
methylation, probably established by cell division and myelin
differentiation.
Demethylation Correlates with Decreased SAMe Levels
SAMe donates its methyl group to a large variety of acceptor
molecules, including histones, DNA, and proteins (Lu and
Mato, 2012). Recent studies have shown that SAMe levels can
regulate histone methylation patterns in several systems
(Shyh-Chang et al., 2013; Towbin et al., 2012; Ulanovskaya
et al., 2013).
To investigate whether availability of SAMe could also
determine the DNA methylation pattern during Schwann cell
myelination, we first examined expression of the genes encoding
the enzymes involved in the biosynthesis and catabolism of
SAMe, which form part of the methionine cycle (Lu and Mato,
2012) (Figure 4A). We found that all the main enzymes were
expressed and were differentially regulated during the myelina-
tion process (Figure 4B). Importantly, we found that the levels
of SAMe were significantly reduced in P60 nerves, compared
to P10 nerves (Figure 4C). In transmethylation reactions, SAH
is produced and acts as a competitive inhibitor of methyltrans-
ferases. The SAMe/SAH ratio provides an important metabolic
indicator of cellular methylation status (Ulanovskaya et al.,
2013) and global hypomethylation has been associated with a
decrease in this ratio (Lu and Mato, 2012). Here, we found about
a 5-fold decrease in the SAMe/SAH ratio in P60 nerves
compared with P10 nerves. These metabolites could not be
measured in NB nerves since an unrealistically high number of
nerves (>250) was required for each out of five replicates.
These results raised the possibility that SAMe could play a role
in establishing the DNA methylation patterns during Schwann
cell myelination, at least for the second phase of the process.
To test this, we examined the effects of exogenous SAMe
treatment on Schwann cell myelination in vitro. Treatment of
purified Schwann cell cultures using cAMP induces upregulation
of several myelin proteins, including Egr2, Mpz, and Periaxin
(Iruarrizaga-Lejarreta et al., 2012). We found that SAMe treat-
ment prevented upregulation of Mpz and Periaxin (Figure 4D).A more physiologic model of in vitro Schwann cell myelination
is coculture of Schwann cells with dorsal root ganglion (DRG)
axons, in which Schwann cells associate with and form myelin
segments around axons. Similar to above, we found that
SAMe treatment significantly reduced the number of MBP+
myelin sheaths (Figure 4E) (63 ± 8 MBP+ myelin sheaths in
control cultures compared to 24 ± 3 MBP+ myelin sheaths in
SAMe-treated cells, n = 6, p < 0.01, Student’s t test) and led to
reduced internodal length (Figure S4A).
Next, we examined whether SAMe could regulate DNA
methylation patterns in Schwann cells in vitro. To show this,
we performed RRBS analysis of Schwann cells after exogenous
SAMe application (Figures S4B and S4C; Table S4). We found
that SAMe-treated cells were characterized by a higher pro-
portion of regions with high methylation levels (Figure 4F) and a
greater number of hypermethylated 1 kb tiles (Figure 4G).
DMRs showed an increased methylation level for 1 kb tiles
(Figure 4H) and all genomic regions analyzed (Figure S4D).
These results indicate that exogenous SAMe application in
Schwann cell cultures lead to global and locus-specific DNA
hypermethylation.
We next examined whether elevated SAMe levels could also
affect Schwann cell myelination and DNA methylation patterns
in vivo. For this, we used mice lacking the Gnmt gene (Gnmt–/–
mice) (Martı´nez-Chantar et al., 2008). GNMT is an enzyme that
is expressed in several tissues, including the liver, where it
metabolizes SAMe to maintain its levels within a tight range
and prevent aberrant methylation reactions (Lu and Mato,
2012; Martı´nez-Chantar et al., 2008). As shown above, Gnmt
was also expressed in Schwann cells, and notably it was signif-
icantly upregulated in P60 nerves compared to P10 nerves (Fig-
ure 4B), correlating with a decrease in SAMe levels (Figure 4C).
P90 sciatic nerves from Gnmt–/– mice did not express GNMT
(Figure 5A), and this resulted in a 2-fold increase in SAMe con-
centration and SAMe/SAH ratio (Figure 5B).
Peripheral nerves of Gnmt–/– mice were hypomyelinated
(thinner myelin sheaths), a characteristic feature of several
peripheral neuropathies (Suter and Scherer, 2003) (Figure 5C),
which was confirmed quantitatively using G-ratio measurements
(Figure 5D). The hypomyelination phenotype was unlikely to be
due to defects in radial sorting (Woodhoo and Sommer, 2008),
since we did not find any differences in the ratio of myelinating
to promyelinating Schwann cells in P5 nerves (Woodhoo et al.,
2009) or defects in axons, which did not show differences in
diameter in P90 nerves (data not shown).
Microarray analyses showed substantial differential gene
expression profiles, between nerves from Gnmt+/+ and Gnmt–/–
mice (Figure 5E; Table S5), with a greater number of down-
regulated than upregulated genes. GO analyses showed that
the most significant category associated with the down-
regulated genes was lipid metabolism, which could probably
explain the hypomyelination profile in the Gnmt–/– nerves (Fig-
ure 5F; Table S5).
Elevated SAMe Levels In Vivo Leads to DNA
Hypermethylation
The elevated SAMe concentration in the nerves of the Gnmt–/–
mice raised the interesting possibility that the myelinationNeuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1029
Figure 4. SAMe Levels Are Reduced during Schwann Cell Myelination, and SAMe Supplementation Blocks Schwann Cell Myelination In Vitro
(A) Schematic representation of the methionine cycle, in which the site of action of different enzymes involved (blue) is shown.
(B) qPCR analysis showing differential expression of the main genes involved in the methionine cycle during Schwann cell myelination. Data are represented as
mean ± SEM, *p < 0.01, n = 3, Student’s t test.
(C) Table showing levels of the metabolites methionine, SAMe, and SAH (pmol mg1 of tissue), and the SAMe/SAH ratio in P10 and P60 nerves. Data are
represented as mean ± SEM, *p < 0.05, n = 5, Student’s t test.
(D) WB showing that exogenous SAMe supplementation prevents upregulation of the myelin proteins Mpz and Periaxin under myelinogenic conditions (cAMP
treatment). b-actin is shown as a loading control.
(E) Immunocytochemistry showing fewerMBP+-myelinated segments (red) in SAMe-treated DRG-Schwann cell cocultures. Note that axonal network (Tuj1+ cells,
green) appears normal in both control and SAMe-treated cultures.
(F) Proportion of 1 kb tiles with high (R80%, green), intermediate (>20% and < 80%, red), and low (%20%, blue) percentage methylation levels in control and
SAMe-treated cultures.
(G) Violin plot showing about a 3-fold greater number of hypermethylated tiling regions (red) in SAMe-treated cultures than hypomethylated tiling regions. Black
dots represent regions with percentage methylation difference <20% and/or q value > 0.05.
(H) Boxplot showing an increased median methylation level in differentially methylated tiling regions.
See also Figure S4 and Table S4.
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Figure 5. Elevated SAMe Levels in Gnmt–/– Mice Lead to Hypomyelination and Gene Expression Changes
(A) WB showing that GNMT is absent in sciatic nerves fromGnmt–/–mice. Liver, where GNMT is highly expressed (representing 1% of total protein) (Lu andMato,
2012), is shown as a control. Ponceau is used as a loading control, since we found that GAPDH and b-actin were respectively downregulated and upregulated in
Gnmt–/– nerves.
(B) Table showing levels of the metabolites methionine, SAMe, and SAH (pmol mg1 of tissue), and the SAMe/SAH ratio in Gnmt+/+ and Gnmt–/– mice. Data are
represented as mean ± SEM, *p < 0.01, n = 5, Student’s t test.
(C) Electron micrographs showing thinner myelin sheaths (red arrows) in nerves from Gnmt–/– mice, compared to normal-sized myelin sheaths in Gnmt+/+ mice
(blue arrows).
(D) Morphometric analysis of myelinated axons in nerves from Gnmt+/+ and Gnmt–/– mice, showing G-ratio measurements, expressed as individual measure-
ments in scatterplot (left) or boxplot (right) (***p < 0.01, n = 5, Student’s t test).
(E) Violin plot showing gene expression changes in Gnmt–/– mice compared to Gnmt+/+ mice, with a higher proportion of downregulated (blue) than upregulated
(red) genes.
(F) GO analysis showing top Molecular and Cellular Function categories enriched in downregulated genes in Gnmt–/– mice.
See also Table S5.
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SAMe Regulates the Schwann Cell DNA Methylomedefects could be due to DNA hypermethylation, as shown for
SAMe-treated cultures above. To show this, we performed
RRBS analysis (Figures S5A–S5C), from which methylation
levels of 61,916 1 kb tiles were obtained (Table S6). We found
that Gnmt–/– nerves were characterized by a higher proportion
of highly methylated regions (Figure 6A) and a greater number
of hypermethylated 1 kb tiles (Figure 6B). DMRs showed an
increased methylation level for 1 kb tiles (Figure 6C) and all
genomic regions analyzed (Figure S5D).Similar to Gnmt–/– nerves in vivo, we found that GNMT
silencing in vitro led to an increase in SAMe levels
and SAMe/SAH ratio (Figures 7A and 7B). RRBS analysis
(Figures S6A and S6B; Table S7) showed that GNMT-
silenced cells were also characterized by a predominantly
DNA hypermethylation phenotype compared to control
cultures (Figures 7C and 7D), suggesting that the DNA
methylation changes in vivo are due to the absence of GNMT
itself.Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1031
Figure 6. Elevated SAMe Levels in Gnmt–/– Mice Lead to Global and Locus-Specific DNA Hypermethylation
(A) Proportion of 1 kb tiles with high (R80%, green), intermediate (>20% and <80%, red), and low (%20%, blue) percentage methylation levels.
(B) Violin plot showing about a 3-fold greater number of hypermethylated tiling regions (red) in Gnmt–/– mice than hypomethylated tiling regions. Black dots
represent regions with percentage methylation difference <20% and/or q value > 0.05.
(C) Boxplot showing an increased median methylation level in differentially methylated tiling regions in Gnmt–/– mice.
(D) Scatterplot of DNA methylation of 1 kb tiles showing hypomethylated regions (blue) and hypermethylated regions (red) in Gnmt–/– mice. Selected hyper-
methylated genes are highlighted (genes that are downregulated are shown in green).
(E) GO analysis showing top Molecular and Cellular Function categories enriched in all downregulated genes hypermethylated at tiling regions or gene regulatory
regions.
(F) Histogram showing most significantly changed lipid species and amino acids in Gnmt–/– mice compared to Gnmt+/+ mice.
See also Figure S5 and Table S6.
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was due to the elevated SAMe levels, we cultured the GNMT-
silenced cells in medium containing low-methionine levels
(MDM). As shown previously for cancer cells with reduced
GNMT expression (Wang et al., 2011), culture of Schwann
cells in this medium prevented the increase in SAMe levels
in cells with lower GNMT expression (Figure 7B). RRBS
analysis showed that the hypermethylation induced by GNMT
knockdown was significantly blocked by culture of these cells
in low-methionine medium (Figures 7E–7J). As a result, the
increased median methylation level induced by GNMT
knockdown was strikingly lowered for 1 kb tiles (Figure 7K) and
all genomic regions analyzed (Figure S6C). These data strongly
suggest that elevated SAMe levels, induced by GNMT
knockdown, are responsible for the DNA hypermethylation in
Schwann cells.1032 Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc.We found that several downregulated genes in Gnmt–/– mice
had increased methylation levels in 1 kb tiles (Figure 6D), several
of which were annotated to promoter regions and putative
enhancer elements (Figure S5E). GO analysis of these genes
showed that the most significant category was lipid metabolism
(Figure 6E; Table S5). A multiplatform metabolomic profiling was
performed to examine differences in amino acid and lipid
composition between Gnmt+/+ and Gnmt–/– sciatic nerves. Prin-
cipal component analysis (PCA) of all metabolites analyzed
showed clear sample segregation according to mice genotype
(Figure S5F), and we identified several lipid species that signifi-
cantly contributed to these differences (Figure 6F and Fig-
ure S5G; Table S6).
These results indicate that elevated SAMe concentration in
Gnmt–/– mice leads to global and locus-specific DNA hyper-
methylation, which correlates with a downregulation of several
Neuron
SAMe Regulates the Schwann Cell DNA Methylomelipid metabolism genes. This probably leads to the altered lipid
profile and peripheral nerve defects in these mice.
Reduced SAMe Levels Could Be Responsible for
Pathogenesis of Diabetic Mice
Our results above argue for a key role of DNA methylation during
Schwann cell myelination and suggest that aberrant DNA
methylation patterns can lead to defects in peripheral nerve
myelination. There are several pathological conditions, which
can cause malformation or destruction of myelin sheaths.
Diabetic neuropathy is the most common and debilitating
complication of diabetes, with injury to axons and Schwann cells
both contributing to the pathogenesis of the disease (Vincent
et al., 2011). It is a distinct possibility that peripheral nerves in
this pathological situation could be characterized by aberrant
DNA methylation patterns.
To show this, we performed a genome-wide analysis of the
methylation pattern in 6-month-old db/db mice, a mouse model
of diabetic neuropathy, which closely resembles the human
condition (Pande et al., 2011). RRBS analysis was performed
(Figures S7A–S7C), from which methylation levels of 65,534 1
kb tiles were obtained for comparison (Table S8). There was a
small reduction in proportion of highly methylated regions (Fig-
ure 8A) and analysis of DMRs showed twice as many hypome-
thylated 1 kb tiles as hypermethylated regions (Figure 8B).
DMRs showed a decreased methylation level for 1 kb tiles (Fig-
ure 8C) and all genomic regions analyzed (Figure S7D).
Using gene expression data sets published previously (Pande
et al., 2011), we found that genes with concomitant changes in
DNA methylation and transcript levels were enriched for func-
tional categories (Figures 8D and 8E; Table S8) that were associ-
ated with the gene expression signature of these mice (Figures
S7E–S7G). For example, for upregulated genes, there was a
significant enrichment in the cellular proliferation category, which
was also one of the most significant categories associated with
hypomethylated genes. Lipid metabolism was another signifi-
cantly enriched category (Table S8), similar to what we found
during developmental myelination and in the Gnmt/ mice.
Next, we examined the mechanisms that could contribute to
these aberrant methylation patterns. We found that expression
of the Dnmt1 mRNA and protein was upregulated in db/db
mice, whereas the expression of other DNA methyltransferases
(Figures 8F and 8G) and demethylases (data not shown) were
unaffected. This was consistent with DNA hypermethylation of
several regions, but not with hypomethylation (Figures 8B and
8C). We thus examined whether the predominantly hypomethy-
lated phenotype could instead be associated with SAMe levels.
We found that db/db mice expressed more GNMT (Figures 8H
and 8I) and, importantly, we found that the nerves from these
mice had a lower SAMe content and SAMe/SAH ratio than con-
trol mice (Figure 8J). Interestingly, we found that this reduced
SAMe content and SAMe/SAH ratio seen in the aged mice was
already present in 8-week-old db/db mice, when neuropathy
had developed, but not in 4-week-old mice, which are character-
ized by diabetes but have not yet developed neuropathy
(Figure S7H).
Based on our previous results, we propose that the global DNA
demethylation seen in this model of diabetic neuropathy couldresult from the reduced SAMe levels and lower SAMe/SAH ratio
in thesemice, due to the increasedGNMT expression. This could
play a role in the pathogenesis of the disease, possibly even at
the onset of the disease. It would be an interesting possibility,
in future studies, to examine whether administering SAMe to
db/db mice could help prevent the DNA hypomethylation, and
consequently, the nerve pathology in these mice.DISCUSSION
Schwann cell myelination is a highly orchestrated and complex
developmental process, which requires coordinated and wide-
spread changes in gene expression. The establishment and
maintenance of this gene expression pattern is principally regu-
lated by an elaborate network of TFs (Jessen and Mirsky, 2005;
Pereira et al., 2012). Recently, several studies have shown that
another level of transcriptional control is provided by recruitment
of the NuRD and BAF chromatin-remodeling complexes to reg-
ulatory regions of key myelin genes (Hung et al., 2012; Weider
et al., 2012) and possibly by histone deacetylation by HDAC1
and HDAC2 (Pereira et al., 2012). In this study, using high-reso-
lution genome-scale maps of methylation patterns, we found
that DNA methylation also is likely to be an essential component
of the global regulatory mechanisms regulating Schwann cell
myelination.The Role of DNA Methylation during Schwann Cell
Myelination
We found that Schwann cell myelination was characterized
by global demethylation, whereas gene expression changes
showed about an equal number of upregulated and down-
regulated genes. This is consistent with DNA methylation being
only one of other concerted factors in regulating gene expres-
sion (Portela and Esteller, 2010). Instead, similarly to other so-
matic cell differentiation systems (Bock et al., 2012; Calvanese
et al., 2012; Lee et al., 2012), DNA demethylation was associ-
ated with activation of myelination-specific genes, notably at
promoter regions and putative enhancer elements. This sug-
gests that DNA methylation could prevent their aberrant
expression in progenitor cells, and loss of methylation could
promote their transcription. These demethylated genes were
significantly enriched for lipid metabolism, which has a critical
function in the generation of the lipid-rich myelin (Chrast
et al., 2011).
In addition to DNA methylation, several different mechanisms,
including TF binding and occupancy, and histone modifications
act coordinately to regulate gene transcription during Schwann
cell myelination (Jessen and Mirsky, 2005; Pereira et al., 2012).
Moreover, microRNAs and regulation of mRNA stability by
RNA-binding proteins also can regulate mRNA levels (Iruarri-
zaga-Lejarreta et al., 2012; Pereira et al., 2012). It is likely that
the selective activation of myelination-specific genes by DNA
demethylation is regulated by a unique concerted action with
several of these factors. This argues for a key function of DNA
methylation as part of the complex network of transcriptional,
posttranscriptional, and epigenetic factors that drive the myeli-
nation program.Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1033
(legend on next page)
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SAMe Regulates the Schwann Cell DNA MethylomeTo perform these studies, we used the sciatic nerve as amodel
to profile DNA methylation changes during the Schwann cell
myelination, a model that has previously been used to generate
gene expression or microRNA profiles (Gokey et al., 2012;
Verheijen et al., 2003). In addition to Schwann cells, the sciatic
nerve consists of other cell types, including fibroblasts, and
our data would probably include DNA methylation profiles of
these cells. However, this effect could be minimal since
Schwann cells represent the majority of the endoneurial cells
of the nerve (Verheijen et al., 2003).
Genomic enrichment classification of DMRs showed that
repeat elements were one of the most significant groups, simi-
larly to erythropoesis, another model of somatic cell differentia-
tion (Shearstone et al., 2011), and in the early embryo and during
germline development (Smith et al., 2012). Endogenous trans-
posable elements consist of three major classes, LINEs, SINEs,
and LTRs, and constitute about 40% of themammalian genome.
DNA methylation is one of the primary mechanisms used for
silencing repeat elements (Beck et al., 2011). There is strong
evidence that transposable elements can influence host gene
expression (Rebollo et al., 2012). Interestingly, in the brain,
LINE-1 retrotransposition, which is controlled by DNA methyl-
ation, can occur and has been suggested to influence neuronal
transcriptomes and function (Muotri et al., 2010). Although
much remains to be learned in this area, it is an interesting
possibility that demethylation of repeat elements during
Schwann cell myelination could lead to a similar increase in
retrotransposition that could play an important role in regulation
of gene expression.
SAMe Levels as a Critical Determinant of the
Methylation Landscape
We found that DNA demethylation during Schwann cell myelina-
tion could be regulated by several mechanisms, including
binding of critical TFs associated with Schwann cell myelinationFigure 7. DNA Hypermethylation Induced by GNMT Silencing In Vitro I
(A) Western blot showing reduced GNMT levels in sh GNMT-infected Schwann ce
(B) Table showing the levels of the metabolites SAMe and SAH (pmol per 2 3 10
cells. Data are represented as mean ± SEM, *p < 0.05, n = 5, Student’s t test. In
prevented by culture in low-methionine medium.
(C) Violin plot showing about a 5-fold greater number of hypermethylated tiling r
compared to control cells. Black dots represent regions with percentage methyl
(D) Boxplot showing an increased median methylation level in differentially meth
(E–K) Increased methylation induced in GNMT-silenced cells is prevented by cu
green), intermediate (>20% and < 80%, red), and low (%20%, blue) percentage
hypermethylated 1 kb tiles in the comparison sh GNMT_v_sh Control. When the
significant decrease in the methylation levels of many of the tiles. (G) Scatterplo
(methylation increase of R20%, q value < 0.05) in the comparison sh GNMT_
(methylation difference of 20%) in the comparison sh GNMT (MDM)_v_sh Contr
GNMT_v_sh Control) classified as hypermethylated DMRs, hypomethylated DMR
(MDM)_v_sh Control. Out of the 12,313 tiles hypermethylated in the comparison
methylation differences (methylation difference of 20% and/or q value > 0.05) in th
methylation levels of 1 kb tiles (12,313 tiles hypermethylated in the comparison s
(MDM) cultures have an overall lower methylation level than sh GNMT cultures.
levels in the comparison shGNMT (MDM)_v_shGNMT. A large number of tiles hav
showing increasedmethylation. (K) Boxplot showing increasedmethylation levels
q value < 0.05) inGNMT-silenced cells cultures (sh GNMT) compared to control cu
low-methionine medium (sh GNMT_MDM).
See also Figure S6 and Table S7.(Jessen andMirsky, 2005; Pereira et al., 2012) to gene regulatory
regions, as established in classical studies (Smith and Meissner,
2013), or cell division, as shown for erythropoiesis (Shearstone
et al., 2011), and by expression of DNMTs and DNA demethy-
lases. In addition, we provide evidence that levels of SAMe,
the principal methyl donor in methylation reactions, could also
be a critical determinant in establishing DNA methylation
patterns. Several studies have associated aberrant DNAmethyl-
ation patternswith the availability of SAMe (Feil and Fraga, 2011).
However, these studies have focused on locus-specific methyl-
ation changes. Our study, instead, provides a comprehensive
analysis of genome-wide DNA methylation changes induced
by alterations in SAMe levels in a biological process. We found
that DNA demethylation during Schwann cell myelination corre-
lates with a decrease in SAMe concentration and, importantly,
elevated SAMe levels in vitro and in vivo lead to DNA hyperme-
thylation globally and in several genomic regions, including
repeat elements, gene promoters and bodies, and enhancers.
Hypermethylation at gene regulatory regions in vivo correlates
with suppression of several genes, which were notably
enriched for the lipid metabolism category. This was probably
the cause of the abnormal lipidomic profile and myelination
defects in these mice. The functional importance of lipid meta-
bolism in peripheral myelination has been shown with mouse
mutants and in human genetic conditions (Chrast et al., 2011).
In one such study, genetic ablation of Scap, the transcriptional
activator of SREBPs, which regulates lipogenesis, leads to
congenital hypomyelination and an abnormal lipid profile, similar
to the Gnmt–/–mice.
Posttranslational modification of histones is another major
component of the regulatory network that controls gene expres-
sion. Histonemethylation can occur at different residues and can
lead to either gene activation or repression to control various
biological processes (Greer and Shi, 2012). Several recent
studies point to an important role of SAMe in regulating histones Reverted by Culture in Low-Methionine Medium
lls compared to sh Control-infected cells. b-Actin is used as a loading control.
6 cells) and the SAMe/SAH ratio in sh Control, sh GNMT, and sh GNMT (MDM)
crease in SAMe levels and the SAMe/SAH ratio induced by GNMT silencing is
egions (red) than hypomethylated tiling regions (blue) in GNMT-silenced cells
ation difference <20% and/or q value > 0.05.
ylated tiling regions.
lture in low-methionine medium. (E) Proportion of 1 kb tiles with high (R80%,
methylation levels. (F) Heatmap showing the absolute methylation levels of all
GNMT-silenced cells were cultured in low-methionine medium, there was a
t showing that the large majority of tiles classified as hypermethylated DMRs
v_sh Control (red) did not show significant differences in methylation levels
ol (blue). (H) Counts of the tiles (hypermethylated DMRs in the comparison sh
s, or with no change (methylation difference <20%) in the comparison sh GNMT
sh GNMT_v_sh Control, about 75% of them (9,146) did not show significant
e comparison sh GNMT (MDM)_v_sh Control. (I) Scatterplot of percentage DNA
h GNMT_v_sh Control) in sh GNMT and sh GNMT (MDM) cultures. sh GNMT
(J) Graph showing the proportion of tiles with different changes in methylation
e a decreasedmethylation level of at least 25%, with aminimum number of tiles
of all differentially methylated 1 kb tiling regions (methylation difference of 20%,
ltures (sh Control). This effect is abolishedwhen shGNMT cells were cultured in
Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc. 1035
Figure 8. DNA Is Globally Hypomethylated in db/db Mice at P180, Correlating with Reduced SAMe Levels
(A) Proportion of 1 kb tiles with high (R80%, green), intermediate (>20% and <80%, red), and low (%20%, blue) percentage methylation levels.
(B) Violin plot showing about a 2-fold greater number of hypomethylated tiling regions (blue) in db/db mice compared to db/+ mice.
(C) Boxplot showing a decreased methylation level in differentially methylated tiling regions in db/db mice.
(D) GO analysis showing top Molecular and Cellular Function categories enriched in upregulated genes that are hypomethylated at tiling regions or gene
regulatory regions.
(E) GO analysis showing top Molecular and Cellular Function categories enriched in all downregulated genes that are hypermethylated at tiling regions or gene
regulatory regions.
(F and G) Dnmt1 is upregulated in nerves from db/db mice, as shown by qPCR analysis (F) and western blotting (G).
(H) qPCR analysis showing relative transcript levels of enzymes involved in methionine cycle. Data are represented as mean ± SEM, *p < 0.01, n = 3, Student’s t
test.
(I) Western blot analysis confirming higher GNMT expression in db/db mice.
(J) Table showing levels of the metabolites methionine, SAMe, and SAH (pmol mg1 of tissue), and the SAMe/SAH ratio in db/+ and db/db mice. Data are
represented as mean ± SEM, *p < 0.01, n = 5, Student’s t test.
See also Figure S7 and Table S8.
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SAMe Regulates the Schwann Cell DNA Methylomemethylation (Shyh-Chang et al., 2013; Towbin et al., 2012;
Ulanovskaya et al., 2013). Histone methylation is likely to play
an important role in regulating gene expression in Schwann cells.1036 Neuron 81, 1024–1039, March 5, 2014 ª2014 Elsevier Inc.However, further studies are required to determine the contribu-
tion of SAMe to establishing histone methylation patterns during
Schwann cell myelination.
Neuron
SAMe Regulates the Schwann Cell DNA MethylomeSAMe as Part of the Pathogenetic Mechanisms of
Common Diseases
Epigeneticmechanisms play a fundamental role in the pathogen-
esis of a growing list of human diseases, including cancer and
neurological diseases (Portela and Esteller, 2010). Recently, it
was shown that the leprosy bacterium can induce reprogram-
ming of Schwann cells to cells with stem-cell-like properties,
by altering DNA methylation status of critical genes (Masaki
et al., 2013). Here, we show that diabetic neuropathy is charac-
terized by an aberrantly demethylated DNA profile, possibly
determined by the reduced SAMe concentration and SAMe/
SAH ratio as a result of increased GNMT expression. SAMe
levels are influenced by a variety of environmental factors, in
addition to diabetes, including diet (Choi and Friso, 2010) and
viral infections (Bottiglieri, 2002), which are also known to cause
peripheral neuropathies. It is a distinct possibility that altered
SAMe levels could contribute to the pathogenesis of these
acquired neuropathies, through aberrant methylation of DNA
and histones. Such a mechanism could also contribute to other
neurological pathologies. For example, Alzheimer’s disease is
also characterized by changes in DNA methylation patterns
(Cyr and Domann, 2011), and recently decreased levels
of SAMe were found in cerebrospinal fluid of patients with
Alzheimer’s disease (Linnebank et al., 2010).
In conclusion, we show that myelination is characterized by
DNA demethylation, which is associated with activation of
differentiation-specific genes, and that local availability of
SAMe is likely to play a critical role in regulating the methylation
pattern during this process. Our results also suggest that SAMe
could play a role in the establishment of the aberrant DNA
methylation patterns in a mouse model of diabetic neuropathy.
This study, together with other studies on the influence of
SAMe on histonemethylation, supports the view that the methyl-




Mice and rats were housed at the animal unit at CIC bioGUNE (AAALAC-
accredited facility). All procedures were approved by the institutional commit-
tee on animal use. Sciatic nerves were isolated from C57 BL6/J mice at NB,
P10, and P60 ages. Gnmt–/– mice were described previously (Martı´nez-Chan-
tar et al., 2008) and nerves were isolated at P90. db/db mice, as described
previously (Pande et al., 2011), were purchased from Jackson Laboratories
and nerves were extracted at P180. Nerves from mice of either sex were
used. Immediately after isolation, nerves were desheathed and flash frozen
in liquid nitrogen.
Reduced Representation Bisulfite Sequencing
Preparation of RRBS libraries was adapted from published protocols (Gu et al.,
2011), and libraries were sequenced by the CIC bioGUNE Genome Analysis
Platform on a HiScanSQ platform (Illumina). Details of RRBS analysis and bio-
informatic analysis are provided in Supplemental Experimental Procedures.
Gene Expression Microarray Analysis
Total RNA was isolated from different sets of nerves using standard tech-
niques and cRNA libraries hybridized to the MOUSEWG-6 V2 BeadChips (Illu-
mina). Data were processed as described in Iruarrizaga-Lejarreta et al. (2012).
Adjustment of p values was done by the determination of false discovery rate
(FDR) using Benjamini-Hochberg procedure.Primary Schwann Cell Culture and cAMP Myelination Assay
Schwann cells were isolated from P5 sciatic nerves of Wistar rats or P5–P8
sciatic nerves from C57 BL6/J mice and purified and cultured as described
before (Iruarrizaga-Lejarreta et al., 2012), except that horse serum was used
instead of FBS for mouse Schwann cells. Only the first five passages were
used. For myelination assays, a cAMP analog, dibutryl cAMP (103 M), was
added to cultures for 2 days. For mouse Schwann cells, the medium was
also supplemented with NRG1 (10 ng ml1).
Viral Infection
Cells were treated with control lentiviral particles (pLKO.1) or short-hairpin
lentiviral particles against GNMT (Sigma Mission clone: TRCN0000097601)
in the presence of hexadimethrine bromide (8 mg ml1). After 24 hr transduc-
tion, the cells were selected using puromycin (1.25 mg ml1).
S-Adenosylmethionine Treatment
SAMe, in the stable form of sulfate-p-toluensulfonate (Samyr), was obtained
from Abbott or Sigma and used freshly prepared at a concentration of 2 mM.
In Vitro RRBS Analysis
(1) Purifiedmouse Schwann cells cultured undermyelinogenic conditions were
either treated or untreated for 2 days with SAMe, and then genomic DNA was
extracted for RRBS analysis. (2) Puromycin-selected shControl and shGNMT-
silenced cells were switched to myelinogenic conditions for 2 days, and then
genomic DNA was extracted. For MDM treatment, shGNMT cells were
switched to myelinogenic conditions for 2 days (medium containing 10 mM
methionine) and then genomic DNA was extracted.
Electron Microscopy and Morphometric Analyses
Processing of nerve samples was carried out as described (Woodhoo et al.,
2009) and sections were viewed in a Jeol 1010 transmission electron micro-
scope (TEM). See Supplemental Experimental Procedures for further details.
Metabolite Measurements and Profiling
For quantitative metabolite measurements (SAMe, SAH, or methionine),
several sets of nerves or Schwann cell cultures were pooled together and
analysis performed (Martı´nez-Chantar et al., 2008) at CIC bioGUNE’s Metab-
olomics Platform. Metabolite profiling and analysis were performed at OWL
metabolomics. In brief, three separate ultraperformance liquid chromatog-
raphy-mass spectrometry-based platforms were used for optimal profiling of
(1) fatty acyls, bile acids, and lysoglycerophospholipids; (2) amino acids; and
(3) glycerolipids, cholesteryl esters, sphingolipids, and glycerophospholipids
as described in Barr et al. (2012).ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession number for the RRBS and
microarray data reported in this paper is GSE45702.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.01.037.
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